Home › Free Stock Grades › LCTX
Lineage Cell Therapeutics, Inc. (LCTX) Stock Grade
LCTX · Healthcare
A-
Market Cap
$384.3M
P/E Ratio
—
Revenue Growth (YoY)
+53.2%
Net Margin
-436.5%
Return on Equity
—
Dividend Yield
None
About Lineage Cell Therapeutics, Inc.'s fundamentals
Lineage Cell Therapeutics is a pre-profitability biotechnology company with a market capitalization of $384.3 million that reported strong revenue growth of 53.2% year-over-year, indicating expanding commercial activity. However, the company operates at a significant loss, with a net margin of -436.5%, meaning expenses substantially exceed revenues. As a development-stage biotech firm, the company does not pay dividends and currently has no meaningful earnings, which is typical for companies in early stages of commercializing pipeline therapies.